Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 6:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 135 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: placebo bupropion Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Impact of Smoking Cessation on Sleep - 5

NCT00132821
View directory record Official record
Conditions
Tobacco Use Cessation, Sleep Disorders
Interventions
Bupropion, Transdermal Nicotine Patch, Placebo Bupropion, Placebo transdermal nicotine patch
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 21, 2026, 6:27 AM EDT
Terminated Phase 3 Interventional Results available

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

NCT01601704
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NB32, PBO, Weight Management Program
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
45 Years and older
Enrollment
8,910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
224
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 221 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 21, 2026, 6:27 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Bupropion and Restless Legs Syndrome

NCT00621517
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Bupropion, Placebo
Drug
Lead sponsor
East Tennessee State University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Johnson City, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 21, 2026, 6:27 AM EDT
Active, not recruiting Phase 2 Interventional

Combination of Novel Therapies for CKD Comorbid Depression

NCT04422652
View directory record Official record
Conditions
Chronic Kidney Diseases, Major Depressive Disorder, End Stage Kidney Disease (ESRD)
Interventions
Bupropion, Behavioral activation therapy, Placebo, Clinical Management
Drug · Behavioral · Other
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
Stony Brook, New York • Dallas, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 21, 2026, 6:27 AM EDT
Withdrawn Phase 4 Interventional

Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery

NCT02616315
View directory record Official record
Conditions
Weight Regain Post Bariatric Surgery
Interventions
Naltrexone HCl/Bupropion HCl Placebo, Naltrexone HCl/Bupropion HCl
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Sep 21, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Results available

Pilot Trial of Bupropion Versus Placebo for Methamphetamine Abuse in Adolescents

NCT00994448
View directory record Official record
Conditions
Adolescent Methamphetamine Abuse
Interventions
Bupropion SR 150mg tabs, Placebo tablets
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
14 Years to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 21, 2026, 6:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

NCT01574703
View directory record Official record
Conditions
Smoking Cessation
Interventions
placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
4,595 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
65
States / cities
Mobile, Alabama • Encino, California • Escondido, California + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 21, 2026, 6:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Combining Varenicline and Bupropion for Smoking Cessation

NCT00943618
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline, Bupropion, Placebo, Counseling/Phone Calls
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
25 Years to 70 Years
Enrollment
641 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 21, 2026, 6:27 AM EDT
Completed Phase 1 Interventional

The Effects of Acute Administration of Bupropion on Neural Substrates Underlying Hedonic Capacity

NCT00205946
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Bupropion, Placebo
Drug
Lead sponsor
Affective Neuroscience Laboratory
Other
Eligibility
18 Years to 64 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Sep 21, 2026, 6:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals - 3

NCT00136786
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Memantine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2018 · Synced Sep 21, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia

NCT00218218
View directory record Official record
Conditions
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder, Schizophrenia
Interventions
Transdermal Nicotine Patch, 21 mg transdermal nicotine, placebo patch
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 21, 2026, 6:27 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program

NCT00456521
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 32 mg/ bupropion SR 360 mg/ day, Placebo, Intensive group lifestyle modification counseling
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
La Jolla, California • Denver, Colorado • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Sep 21, 2026, 6:27 AM EDT
Completed Phase 4 Interventional Results available

Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers

NCT01048944
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Bupropion SR, Nicotine Patch, Placebo Patch and Placebo Pill
Drug
Lead sponsor
Southern Illinois University Carbondale
Other
Eligibility
18 Years to 55 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Carbondale, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Sep 21, 2026, 6:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Bupropion Alone or Combined With Nicotine Gum

NCT01621022
View directory record Official record
Conditions
Tobacco Dependence
Interventions
bupropion + nicotine gum, Active bupropion-Placebo gum, Placebo bupropion-Placebo gum
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2002
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Sep 21, 2026, 6:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

NCT02735603
View directory record Official record
Conditions
Heart Repolarization
Interventions
Naltrexone HCl/bupropion HCl, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Sep 21, 2026, 6:27 AM EDT
Completed Phase 2Phase 3 Interventional

A Trial of Wellbutrin for Crohn's Disease

NCT00126373
View directory record Official record
Conditions
Crohn Disease
Interventions
Wellbutrin (bupropion)
Drug
Lead sponsor
Altschuler, Eric, M.D.
Individual
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Sep 21, 2026, 6:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Memantine and Bupropion on Acute, Reinforcing, and Conditioned Effects of Cigarettes - 1

NCT00136747
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Memantine, bupropion, placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2018 · Synced Sep 21, 2026, 6:27 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects

NCT00567255
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 32 mg/bupropion SR 360 mg/day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Carmichael, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 21, 2026, 6:27 AM EDT
Completed Not applicable Interventional Results available

Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo

NCT02317744
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
Naltrexone and bupropion combination, Pill Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Sep 21, 2026, 6:27 AM EDT
Completed Phase 2 Interventional

Pharmacologic Relapse Prevention for Alcoholic Smokers

NCT00000457
View directory record Official record
Conditions
Alcoholism, Smoking
Interventions
bupropion (Wellbutrin), Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 20, 2013 · Synced Sep 21, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression

NCT01407094
View directory record Official record
Conditions
Depression
Interventions
Sertraline, Placebo, BupropionXL
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
296 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Sep 21, 2026, 6:27 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)

NCT04605081
View directory record Official record
Conditions
Loss-of-Control Eating, Obesity/Overweight
Interventions
Naltrexone and Bupropion (NB) medication, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 21, 2026, 6:27 AM EDT
Completed Phase 3 Interventional

Assessing Clinical Outcomes in Alzheimer's Disease Agitation

NCT04797715
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor
Interventions
AXS-05, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
61
States / cities
Sun City, Arizona • Tucson, Arizona • Chula Vista, California + 55 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 21, 2026, 6:27 AM EDT
Completed Phase 1Phase 2 Interventional

A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Affective Disorder

NCT00593099
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Bupropion, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 21, 2026, 6:27 AM EDT